vs

Side-by-side financial comparison of Empire State Realty Trust, Inc. (ESRT) and REPLIGEN CORP (RGEN). Click either name above to swap in a different company.

REPLIGEN CORP is the larger business by last-quarter revenue ($197.9M vs $190.3M, roughly 1.0× Empire State Realty Trust, Inc.). REPLIGEN CORP runs the higher net margin — 6.7% vs 1.6%, a 5.1% gap on every dollar of revenue. On growth, REPLIGEN CORP posted the faster year-over-year revenue change (13.6% vs 5.7%). Over the past eight quarters, REPLIGEN CORP's revenue compounded faster (14.4% CAGR vs 0.2%).

Empire State Realty Trust is a leading real estate investment trust that owns, manages, and operates a portfolio of premium commercial, residential, and retail properties primarily in the New York City metropolitan area, including the iconic Empire State Building. It serves corporate tenants, retail partners, and residential occupants, focusing on sustainable property operations and long-term asset value growth.

Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs.2025 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biop...

ESRT vs RGEN — Head-to-Head

Bigger by revenue
RGEN
RGEN
1.0× larger
RGEN
$197.9M
$190.3M
ESRT
Growing faster (revenue YoY)
RGEN
RGEN
+7.9% gap
RGEN
13.6%
5.7%
ESRT
Higher net margin
RGEN
RGEN
5.1% more per $
RGEN
6.7%
1.6%
ESRT
Faster 2-yr revenue CAGR
RGEN
RGEN
Annualised
RGEN
14.4%
0.2%
ESRT

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ESRT
ESRT
RGEN
RGEN
Revenue
$190.3M
$197.9M
Net Profit
$3.0M
$13.3M
Gross Margin
52.5%
Operating Margin
15.5%
9.0%
Net Margin
1.6%
6.7%
Revenue YoY
5.7%
13.6%
Net Profit YoY
-73.7%
143.9%
EPS (diluted)
$0.20
$0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESRT
ESRT
RGEN
RGEN
Q1 26
$190.3M
Q4 25
$199.2M
$197.9M
Q3 25
$197.7M
$188.8M
Q2 25
$191.3M
$182.4M
Q1 25
$180.1M
$169.2M
Q4 24
$197.6M
$174.1M
Q3 24
$199.6M
$154.9M
Q2 24
$189.5M
$154.1M
Net Profit
ESRT
ESRT
RGEN
RGEN
Q1 26
$3.0M
Q4 25
$32.2M
$13.3M
Q3 25
$13.6M
$14.9M
Q2 25
$11.4M
$14.9M
Q1 25
$15.8M
$5.8M
Q4 24
$18.8M
$-30.3M
Q3 24
$22.8M
$-654.0K
Q2 24
$28.6M
$3.3M
Gross Margin
ESRT
ESRT
RGEN
RGEN
Q1 26
Q4 25
52.5%
Q3 25
53.2%
Q2 25
50.0%
Q1 25
53.6%
Q4 24
26.1%
Q3 24
50.0%
Q2 24
49.8%
Operating Margin
ESRT
ESRT
RGEN
RGEN
Q1 26
15.5%
Q4 25
17.8%
9.0%
Q3 25
19.9%
8.9%
Q2 25
18.4%
7.6%
Q1 25
14.3%
3.9%
Q4 24
21.7%
-17.7%
Q3 24
22.7%
-5.1%
Q2 24
20.8%
1.0%
Net Margin
ESRT
ESRT
RGEN
RGEN
Q1 26
1.6%
Q4 25
16.1%
6.7%
Q3 25
6.9%
7.9%
Q2 25
6.0%
8.2%
Q1 25
8.8%
3.4%
Q4 24
9.5%
-17.4%
Q3 24
11.4%
-0.4%
Q2 24
15.1%
2.2%
EPS (diluted)
ESRT
ESRT
RGEN
RGEN
Q1 26
$0.20
Q4 25
$0.11
$0.24
Q3 25
$0.05
$0.26
Q2 25
$0.04
$0.26
Q1 25
$0.05
$0.10
Q4 24
$0.07
$-0.55
Q3 24
$0.08
$-0.01
Q2 24
$0.10
$0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESRT
ESRT
RGEN
RGEN
Cash + ST InvestmentsLiquidity on hand
$68.8M
$767.6M
Total DebtLower is stronger
$542.2M
Stockholders' EquityBook value
$1.8B
$2.1B
Total Assets
$4.4B
$2.9B
Debt / EquityLower = less leverage
0.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESRT
ESRT
RGEN
RGEN
Q1 26
$68.8M
Q4 25
$132.7M
$767.6M
Q3 25
$154.1M
$748.7M
Q2 25
$94.6M
$708.9M
Q1 25
$187.8M
$697.2M
Q4 24
$385.5M
$757.4M
Q3 24
$421.9M
$784.0M
Q2 24
$535.5M
$809.1M
Total Debt
ESRT
ESRT
RGEN
RGEN
Q1 26
Q4 25
$542.2M
Q3 25
$537.9M
Q2 25
Q1 25
Q4 24
$525.6M
Q3 24
Q2 24
Stockholders' Equity
ESRT
ESRT
RGEN
RGEN
Q1 26
$1.8B
Q4 25
$1.1B
$2.1B
Q3 25
$1.0B
$2.1B
Q2 25
$1.0B
$2.1B
Q1 25
$1.0B
$2.0B
Q4 24
$1.0B
$2.0B
Q3 24
$1.0B
$2.0B
Q2 24
$1.0B
$2.0B
Total Assets
ESRT
ESRT
RGEN
RGEN
Q1 26
$4.4B
Q4 25
$4.5B
$2.9B
Q3 25
$4.1B
$2.9B
Q2 25
$4.1B
$2.9B
Q1 25
$4.1B
$2.9B
Q4 24
$4.5B
$2.8B
Q3 24
$4.4B
$2.8B
Q2 24
$4.4B
$2.9B
Debt / Equity
ESRT
ESRT
RGEN
RGEN
Q1 26
Q4 25
0.26×
Q3 25
0.26×
Q2 25
Q1 25
Q4 24
0.27×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESRT
ESRT
RGEN
RGEN
Operating Cash FlowLast quarter
$25.7M
Free Cash FlowOCF − Capex
$17.6M
FCF MarginFCF / Revenue
8.9%
Capex IntensityCapex / Revenue
10.0%
4.1%
Cash ConversionOCF / Net Profit
1.93×
TTM Free Cash FlowTrailing 4 quarters
$93.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESRT
ESRT
RGEN
RGEN
Q1 26
Q4 25
$249.1M
$25.7M
Q3 25
$105.3M
$48.1M
Q2 25
$26.7M
$28.6M
Q1 25
$83.1M
$15.0M
Q4 24
$260.9M
$39.2M
Q3 24
$102.8M
$49.3M
Q2 24
$37.1M
$42.2M
Free Cash Flow
ESRT
ESRT
RGEN
RGEN
Q1 26
Q4 25
$50.6M
$17.6M
Q3 25
$72.8M
$43.4M
Q2 25
$-55.1M
$21.5M
Q1 25
$41.1M
$11.4M
Q4 24
$88.0M
$33.6M
Q3 24
$-65.1M
$42.3M
Q2 24
$19.5M
$37.4M
FCF Margin
ESRT
ESRT
RGEN
RGEN
Q1 26
Q4 25
25.4%
8.9%
Q3 25
36.8%
23.0%
Q2 25
-28.8%
11.8%
Q1 25
22.8%
6.8%
Q4 24
44.5%
19.3%
Q3 24
-32.6%
27.3%
Q2 24
10.3%
24.3%
Capex Intensity
ESRT
ESRT
RGEN
RGEN
Q1 26
10.0%
Q4 25
99.6%
4.1%
Q3 25
16.5%
2.5%
Q2 25
42.8%
3.9%
Q1 25
23.4%
2.1%
Q4 24
87.5%
3.2%
Q3 24
84.1%
4.5%
Q2 24
9.3%
3.1%
Cash Conversion
ESRT
ESRT
RGEN
RGEN
Q1 26
Q4 25
7.74×
1.93×
Q3 25
7.72×
3.23×
Q2 25
2.35×
1.92×
Q1 25
5.27×
2.57×
Q4 24
13.88×
Q3 24
4.51×
Q2 24
1.30×
12.70×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESRT
ESRT

Rental revenue (1)$166.1M87%
Observatory revenue$18.5M10%
Other revenue and fees$4.1M2%
Lease termination fees$1.4M1%
Third-party management and other fees$277.0K0%

RGEN
RGEN

Segment breakdown not available.

Related Comparisons